LAROPIPRANT
LAROPIPRANT 性质
| 熔点 | 175∶C |
|---|---|
| 沸点 | 710.0±60.0 °C(Predicted) |
| 密度 | 1.48 |
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | DMSO:20.0(最大浓度 mg/mL);45.88(最大浓度 mM) DMF:20.0(最大浓度 mg/mL);45.88(最大浓度 mM) DMSO:PBS ( pH 7.2) (1:1):0.5(最大浓度 mg/mL);1.45(最大浓度 mM) 乙醇:5.0(最大浓度 mg/mL);11.47(最大浓度 mM) |
| 形态 | 粉末 |
| 酸度系数(pKa) | 4.54±0.10(Predicted) |
| 颜色 | 白色至米白色 |
| InChIKey | NXFFJDQHYLNEJK-CYBMUJFWSA-N |
| SMILES | OC(C[C@@H](CC1)C2=C1C3=CC(F)=CC(S(C)(=O)=O)=C3N2CC4=CC=C(C=C4)Cl)=O |
LAROPIPRANT 用途与合成方法
|
DP/DP1 Receptor 0.57 nM (Ki) |
TP Receptor 2.95 nM (Ki) |
Laropiprant is a potent, selective DP receptor antagonist with K i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.. Laropiprant (1 µM) causes a significant inhibition of the aggregation but still counteractes the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant blocks DP receptor-dependent increase in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (10 µM) and niacin inhibit in vitro thrombus formation.
LAROPIPRANT 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-50175 | 571170-77-9 | 1 mg | 279 | |
| 2026-09-15 | HY-50175 | LAROPIPRANT | 571170-77-9 | 5mg | 614 |
